---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-099419"
form_type: "8-K"
ticker: "LBRX"
cik: "0001691082"
company_name: "LB PHARMACEUTICALS INC"
filed_at: "2026-03-10T23:59:59+00:00"
generated_at: "2026-05-15T16:44:58.402321+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# LB Pharmaceuticals appoints Dr. Robert Lenz to Board and promotes Gad Soffer to COO

## Summary
- Robert Lenz, M.D., Ph.D., appointed to Board as Class I director; brings over 20 years of neuroscience R&D experience.
- Lenz receives $40,000 annual retainer, $5,000 for Nominating Committee, and initial option grant of 20,000 shares.
- Gad Soffer promoted from Chief Business Officer to Chief Operating and Business Officer, effective March 4, 2026.
- Soffer's annual base salary increased to $505,000 with target bonus of 40% of base salary.
- Lenz previously served as EVP R&D at Neumora Therapeutics and SVP Global Development at Amgen.

## SEC filing metadata
- accession: 0001193125-26-099419
- form_type: 8-K
- ticker: LBRX
- cik: 0001691082
- company_name: LB PHARMACEUTICALS INC
- filed_at: 2026-03-10T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1691082/000119312526099419/0001193125-26-099419-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1691082/000119312526099419/d181430d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-099419
- JSON: https://secwatch.observer/filing/0001193125-26-099419.json
- Plain text: https://secwatch.observer/filing/0001193125-26-099419.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.